Preliminary evidence for the integration of CNAs, CN‑LOH and mutational profiles into the prognostic stratification of elderly patients with <em>NPM1</em>‑mutated acute myeloid leukemia

Gao,Li; Zhang,Chunxia; Gong,Ming; Cao,Zhengyi; Liu,Chundi; Wang,Sijie; Li,Zhenling

doi:10.3892/ol.2026.15499

April-2026 Volume 31 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2026 Volume 31 Issue 4

Full Size Image

Article Open Access

Preliminary evidence for the integration of CNAs, CN‑LOH and mutational profiles into the prognostic stratification of elderly patients with NPM1‑mutated acute myeloid leukemia

Authors:
- Li Gao
- Chunxia Zhang
- Ming Gong
- Zhengyi Cao
- Chundi Liu
- Sijie Wang
- Zhenling Li
View Affiliations / Copyright

Affiliations: Department of Hematology, China‑Japan Friendship Hospital, Beijing 100029, P.R. China

Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].
Article Number: 146
|
Published online on: February 25, 2026

https://doi.org/10.3892/ol.2026.15499
Expand metrics +

Abstract

Acute myeloid leukemia (AML) exhibits substantial genetic heterogeneity in elderly patients. Although validated genomic alterations have improved precision prognostication, incomplete integration of genetic profiles, particularly the underutilization of copy number alterations (CNAs) and copy‑neutral loss of heterozygosity (CN‑LOH), contributes to prognostic uncertainty in elderly patients with nucleophosmin 1 (NPM1)‑mutated AML. To address this gap, the present exploratory single‑center study evaluated 61 elderly patients with NPM1‑mutated AML. Shallow whole‑genome sequencing was used to detect CNAs and CN‑LOH, and targeted next‑generation sequencing was performed to assess mutations in myeloid‑associated genes. Genomic data were integrated with clinical and laboratory parameters to evaluate their prognostic significance. NPM1 subtype A was the predominant variant, and most patients harbored 4 or 5 concurrent somatic mutations, frequently involving fms‑related receptor tyrosine kinase 3 (FLT3), DNA methyltransferase 3 (DNMT3A), tet methylcytosine dioxygenase 2 (TET2), and isocitrate dehydrogenase 2 (IDH2). Overall, 65.57% of patients harbored CNAs and/or CN‑LOH events, with recurrent genomic aberrations including dup(4)(q11q35) in 4 cases. No significant differences in clinical parameters, complete remission rates or overall survival (OS) were observed between CNA/CN‑LOH‑positive and ‑negative groups. However, univariate survival analysis demonstrated that the OS of patients with ≥5 total mutations or ≥3 CNA/CN‑LOH events was significantly shorter compared with that of other patients. Integrative analysis revealed a trend toward shorter OS in patients with FLT3 internal tandem duplication‑positive AML and ≥2 CNA/CN‑LOH events, and longer OS in patients with IDH2‑mutated AML without CNA/CN‑LOH. Multivariate Cox regression analysis tentatively identified ≥3 CNA/CN‑LOH events and ≥5 total mutations as potential independent predictors of a poor prognosis. These findings provide preliminary evidence that integrating CNA/CN‑LOH burden with mutational profiles may improve risk stratification in elderly patients with NPM1‑mutated AML. However, given the small sample size, single‑center design and lack of external validation, larger multi‑center studies are warranted to assess the robustness of these findings.

View Figures

View References

1	Shimony S, Stahl M and Stone RM: Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 100:860–891. 2025. View Article : Google Scholar
2	Kayser S and Levis MJ: The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 108:308–320. 2023. View Article : Google Scholar
3	Wysota M, Konopleva M and Mitchell S: Novel therapeutic targets in acute myeloid leukemia (AML). Curr Oncol Rep. 26:409–420. 2024. View Article : Google Scholar : PubMed/NCBI
4	Bidet A, Quessada J, Cuccuini W, Decamp M, Lafage-Pochitaloff M, Luquet I, Lefebvre C and Tueur G; Groupe Francophone de Cytogénétique Hématologique (GFCH), : Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). Curr Res Transl Med. 71:1034212023.PubMed/NCBI
5	Snaith O, Poveda-Rogers C, Laczko D, Yang G and Morrissette JJD: Cytogenetics and genomics of acute myeloid leukemia. Best Pract Res Clin Haematol. 37:1015332024. View Article : Google Scholar
6	Falini B, Brunetti L, Sportoletti P and Martelli MP: NPM1-mutated acute myeloid leukemia: From bench to bedside. Blood. 136:1707–1721. 2020. View Article : Google Scholar : PubMed/NCBI
7	Hindley A, Catherwood MA, McMullin MF and Mills KI: Significance of NPM1 gene mutations in AML. Int J Mol Sci. 22:100402021. View Article : Google Scholar
8	Patel SS: NPM1-mutated acute myeloid leukemia: Recent developments and open questions. Pathobiology. 91:18–29. 2024. View Article : Google Scholar : PubMed/NCBI
9	Chen EC, Shimony S, Luskin MR and Stone RM: Biology and management of acute myeloid leukemia with mutated NPM1. Am J Hematol. 100:652–665. 2025. View Article : Google Scholar
10	Giles Doran C and Pennington SR: Copy number alteration signatures as biomarkers in cancer: A review. Biomark Med. 16:371–386. 2022. View Article : Google Scholar : PubMed/NCBI
11	Lyu X, Li T, Zhu D, Cheng Y, Chen Y, He X, Li Z, Li S, Wu W, Geng S, et al: Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 63:2301–2310. 2022. View Article : Google Scholar
12	Mareschal S, Palau A, Lindberg J, Ruminy P, Nilsson C, Bengtzén S, Engvall M, Eriksson A, Neddermeyer A, Marchand V, et al: Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. Blood Adv. 5:1003–1016. 2021. View Article : Google Scholar : PubMed/NCBI
13	Cree IA: The WHO classification of haematolymphoid tumours. Leukemia. 36:1701–1702. 2022. View Article : Google Scholar
14	Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, Görlich D, Krug U, Berdel WE, Woermann BJ, et al: Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 37:1234–1244. 2023. View Article : Google Scholar
15	Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 17:405–424. 2015. View Article : Google Scholar : PubMed/NCBI
16	Jamieson A, Sobral de Barros J, Cochrane DR, Douglas JM, Shankar S, Lynch BJ, Leung S, Martin S, Senz J, Lum A, et al: Targeted and shallow whole-genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers. Clin Cancer Res. 30:2461–2474. 2024. View Article : Google Scholar : PubMed/NCBI
17	McGowan-Jordan J, Hastings RJ and Moore S: An International System for Human Cytogenomic Nomenclature (2020) Reprint of 'Cytogenetic and Genome Research 2020, Vol. 160, No. 7–8S. Karger; Basel, Switzerland: pp. 37–106. 2020
18	Mrózek K: Molecular cytogenetics in acute myeloid leukemia in adult patients: Practical implications. Pol Arch Intern Med. 132:163002022.
19	Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, et al: Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 140:1345–1377. 2022. View Article : Google Scholar
20	Falini B: NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions. Am J Hematol. 98:1452–1464. 2023. View Article : Google Scholar
21	Bhansali RS, Pratz KW and Lai C: Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 16:292023. View Article : Google Scholar
22	Poonsombudlert K, Yodsuwan R, Mott S, Crawford K, Hornberg S, Snow AN, Sutamtewagul G, Magalhaes-Silverman M and Dhakal P: Effect of NPM1 mutation subtype and co-mutation patterns on the outcomes of acute myeloid leukemia. Eur J Haematol. 115:29–35. 2025. View Article : Google Scholar
23	Ishikawa Y, Ushijima Y and Kiyoi H: Recent advances in AML with mutated NPM1. Int J Hematol. 120:556–565. 2024. View Article : Google Scholar
24	Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes A, Gale R, Rapoz-D'Silva T, et al: Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood. 144:714–728. 2024. View Article : Google Scholar : PubMed/NCBI
25	Kishtagari A, Levine RL and Viny AD: Driver mutations in acute myeloid leukemia. Curr Opin Hematol. 27:49–57. 2020. View Article : Google Scholar
26	Shahzad M, Amin MK, Daver NG, Shah MV, Hiwase D, Arber DA, Kharfan-Dabaja MA and Badar T: What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 14:2022024. View Article : Google Scholar : PubMed/NCBI
27	Xu X, Bryke C, Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, et al: Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet. 228–229. 218–235. 2018.
28	Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
29	Salman H: Comparative analysis of AML classification systems: Evaluating the WHO, ICC, and ELN frameworks and their distinctions. Cancers (Basel). 16:29152024. View Article : Google Scholar : PubMed/NCBI
30	Pitel BA, Sharma N, Zepeda-Mendoza C, Smadbeck JB, Pearce KE, Cook JM, Vasmatzis G, Sachs Z, Kanagal-Shamanna R, Viswanatha D, et al: Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J. 11:182021. View Article : Google Scholar : PubMed/NCBI
31	Babakhanlou R, DiNardo C and Borthakur G: IDH2 mutations in acute myeloid leukemia. Leuk Lymphoma. 64:1733–1741. 2023. View Article : Google Scholar